BIT
NBIX icon

BlackRock Institutional Trust’s Neurocrine Biosciences NBIX Stock Holding History

BlackRock Institutional Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$87.7M Buy
2,266,340
+115,391
+5% +$5.22M 0.01% 1010
2016
Q3 		$109M Buy
2,150,949
+136,277
+7% +$6.79M 0.02% 833
2016
Q2 		$91.6M Sell
2,014,672
-16,995
-0.8% -$782K 0.01% 899
2016
Q1 		$80.4M Buy
2,031,667
+902
+0% +$35.8K 0.01% 963
2015
Q4 		$115M Buy
2,030,765
+58,585
+3% +$2.98M 0.02% 763
2015
Q3 		$78.5M Sell
1,972,180
-51,928
-3% -$2.51M 0.01% 976
2015
Q2 		$96.7M Sell
2,024,108
-115,388
-5% -$4.89M 0.02% 905
2015
Q1 		$85M Buy
2,139,496
+100,980
+5% +$3.61M 0.01% 1017
2014
Q4 		$45.5M Sell
2,038,516
-37,226
-2% -$705K 0.01% 1359
2014
Q3 		$32.5M Sell
2,075,742
-3,748
-0.2% -$56K 0.01% 1554
2014
Q2 		$30.8M Sell
2,079,490
-4,359
-0.2% -$61.5K 0.01% 1655
2014
Q1 		$33.5M Buy
2,083,849
+144,026
+7% +$2.46M 0.01% 1590
2013
Q4 		$18.1M Sell
1,939,823
-188,908
-9% -$1.84M ﹤0.01% 2015
2013
Q3 		$24.1M Buy
2,128,731
+234,911
+12% +$3.23M ﹤0.01% 1722
2013
Q2 		$25.3M Buy
+1,893,820
New +$23.3M 0.01% 1623

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock Institutional Trust's NBIX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Neurocrine Biosciences (NBIX) stake by 5.4% in Q4 2016, buying an estimated $5.22M and bringing the position to 2,266,340 shares worth $87.7M. The position accounts for 0.01% of the portfolio, ranked #1010.

BlackRock Institutional Trust first reported a position in NBIX in Q2 2013 and has held it in 15 quarters since. The position peaked at $115M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

  • BlackRock Institutional Trust held 2,266,340 shares of Neurocrine Biosciences worth $87.7M as of Q4 2016.
  • BlackRock Institutional Trust bought 115,391 Neurocrine Biosciences shares in Q4 2016, an estimated $5.22M.
  • Neurocrine Biosciences made up 0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1010 holding.
  • BlackRock Institutional Trust first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Neurocrine Biosciences position peaked at $115M in Q4 2015.
  • 225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.